BioCentury | Apr 15, 2013
Clinical News

Hepagene vaccine and immunotherapeutic data

...doses of Hepagene, 8 lost their HBV DNA viremia. No serious side effects were reported. Medeva PLC...
BioCentury | Apr 15, 2013
Company News

Peptide Therapeutics, Medeva deal

...ordinary shares of PTE for £3.40 per share. Peptide Therapeutics Group plc (LSE:PTE), London, U.K. Medeva PLC...
BioCentury | Dec 2, 2011
Politics & Policy

EU court ruling clarifies SPCs for combo products

...protection certificates (SPCs) before ruling in a suit related to SPC applications from Medeva BV. Medeva...
...EPO) 2009 rejection of its SPC applications for multivalent vaccines. EPO ruled that four of Medeva's...
...supporting patent identified both ingredients, the supporting marketing authorization covered a product with nine ingredients. Medeva...
BioCentury | Aug 21, 2006
Strategy

Targeted Genetics chronicles

...for head and neck cancerF. 4/20/98 - Raises $13.1M in PIPE G. 12/7/98 - Grants Medeva...
BioCentury | Aug 21, 2006
Strategy

Learning through time

...data had begun to elicit interest from potential partners. In October 1998, the company granted Medeva plc...
...it was given back rights to tgAAVCF by Celltech Group plc , which had acquired Medeva...
BioCentury | May 24, 2004
Strategy

UCB's transformation

...molecules, as it acquired these capabilities in its 1999 mergers with Chiroscience Group plc and Medeva plc...
BioCentury | May 24, 2004
Strategy

Celltech's path to acquisition

Celltech's path to acquisition Selected events traced against the weekly stock price of Celltech (LSE:CCH; CLL) in pence over the past five years. A.6/15/99Chiroscience merger announced; CCH 6/14/99 Mcap = £364.8M ($591M)B.8/6/99Chiroscience merger completedC.11/11/99Medeva acquisition...
BioCentury | Oct 27, 2003
Finance

Where to play the game

...add to its London listing in January 2000 as a result of its merger with Medeva plc...
BioCentury | Sep 1, 2003
Strategy

Celltech: Building critical mass

...to Medeva plc (Leatherhead, U.K.). Indeed, the Chiroscience acquisition was completed in August 1999 and the Medeva...
...announced in November (see BioCentury, Nov. 12, 1999). According to Fellner, the markets didn’t like Medeva’s...
...C. 11/11/99 - Medeva announcement; CCH 11/10/99 mkt cap = £732.9M ($1.2B) D. 1/26/00 - Medeva...
BioCentury | Aug 4, 2003
Strategy

Bellwether thinking

...CCH reached its current stage of development by merging with Chiroscience Group plc in 1999, Medeva...
...Thiemann Arzneimittel GmbH in 2001. This year CCH acquired Oxford GlycoSciences plc . While the Medeva...
...including a cough suppressant, a diuretic and treatments for ADHD. However, Ando argued that the Medeva...
Items per page:
1 - 10 of 142
BioCentury | Apr 15, 2013
Clinical News

Hepagene vaccine and immunotherapeutic data

...doses of Hepagene, 8 lost their HBV DNA viremia. No serious side effects were reported. Medeva PLC...
BioCentury | Apr 15, 2013
Company News

Peptide Therapeutics, Medeva deal

...ordinary shares of PTE for £3.40 per share. Peptide Therapeutics Group plc (LSE:PTE), London, U.K. Medeva PLC...
BioCentury | Dec 2, 2011
Politics & Policy

EU court ruling clarifies SPCs for combo products

...protection certificates (SPCs) before ruling in a suit related to SPC applications from Medeva BV. Medeva...
...EPO) 2009 rejection of its SPC applications for multivalent vaccines. EPO ruled that four of Medeva's...
...supporting patent identified both ingredients, the supporting marketing authorization covered a product with nine ingredients. Medeva...
BioCentury | Aug 21, 2006
Strategy

Targeted Genetics chronicles

...for head and neck cancerF. 4/20/98 - Raises $13.1M in PIPE G. 12/7/98 - Grants Medeva...
BioCentury | Aug 21, 2006
Strategy

Learning through time

...data had begun to elicit interest from potential partners. In October 1998, the company granted Medeva plc...
...it was given back rights to tgAAVCF by Celltech Group plc , which had acquired Medeva...
BioCentury | May 24, 2004
Strategy

UCB's transformation

...molecules, as it acquired these capabilities in its 1999 mergers with Chiroscience Group plc and Medeva plc...
BioCentury | May 24, 2004
Strategy

Celltech's path to acquisition

Celltech's path to acquisition Selected events traced against the weekly stock price of Celltech (LSE:CCH; CLL) in pence over the past five years. A.6/15/99Chiroscience merger announced; CCH 6/14/99 Mcap = £364.8M ($591M)B.8/6/99Chiroscience merger completedC.11/11/99Medeva acquisition...
BioCentury | Oct 27, 2003
Finance

Where to play the game

...add to its London listing in January 2000 as a result of its merger with Medeva plc...
BioCentury | Sep 1, 2003
Strategy

Celltech: Building critical mass

...to Medeva plc (Leatherhead, U.K.). Indeed, the Chiroscience acquisition was completed in August 1999 and the Medeva...
...announced in November (see BioCentury, Nov. 12, 1999). According to Fellner, the markets didn’t like Medeva’s...
...C. 11/11/99 - Medeva announcement; CCH 11/10/99 mkt cap = £732.9M ($1.2B) D. 1/26/00 - Medeva...
BioCentury | Aug 4, 2003
Strategy

Bellwether thinking

...CCH reached its current stage of development by merging with Chiroscience Group plc in 1999, Medeva...
...Thiemann Arzneimittel GmbH in 2001. This year CCH acquired Oxford GlycoSciences plc . While the Medeva...
...including a cough suppressant, a diuretic and treatments for ADHD. However, Ando argued that the Medeva...
Items per page:
1 - 10 of 142